Telix Pharmaceuticals Program Update Q3 2019

Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3, 2019.

Telix Pharmaceuticals Program Update Q3 2019

MELBOURNE (Australia) – 4th November 2019 – Telix Pharmaceuticals Limted Program Update Q3, 2019

Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3, 2019.

To read the full media release click here.

* indicates required

First Name *

Last Name *

Email Address *

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Our Company
Contact
Our Portfolio
Careers
Investor Centre
News & Views

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Telix Pharmaceuticals Program Update Q3 2019

Subscribe